The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies

Authors

Institutions

Publication Details

Journal
Drugs in R&D
Published
2026-03-28
DOI
https://doi.org/10.1007/s40268-026-00537-w
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies

E. Daalman, Shilpa Madari, Kathrin Hohl, Brett A. English et al.
Drugs in R&D
Diabetes Treatment and Management
article

The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies

E. Daalman, Shilpa Madari, Kathrin Hohl, Brett A. English, M. Desch, Yury Shatillo, Atef Halabi, Nathalie Weidinger, HeeJae Choi
article en

Abstract

No abstract available for this paper.
Drugs in R&D
Boehringer Ingelheim (Germany) (DE), Clinical Research Services (DE), Boehringer Ingelheim (United States) (US)
Good health and well-being
Openalex Percentile: Top 4%
Diabetes Treatment and Management
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.